MabVax Therapeutics (MBVXQ) Stock Price, News & Analysis

Company Overview

MabVax Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of antibody-based immunotherapies and companion imaging agents for the treatment of cancer. The company’s lead therapeutic candidate, MVT-5873, is a fully human monoclonal antibody that targets carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), which is overexpressed in a variety of solid tumors, including pancreatic, colorectal and gastric cancers. In parallel with its therapeutic program, MabVax is developing MVT-2163, a zirconium-89 labeled PET imaging agent designed to noninvasively detect CEACAM6 expression in tumors, supporting patient selection and treatment monitoring.

Founded in 2012 and headquartered in San Diego, California, MabVax operates primarily in the United States while engaging with academic and clinical research centers to advance its pipeline. The company’s business model leverages in-house research and strategic partnerships to carry candidates through preclinical studies and early-stage clinical trials. MabVax holds global rights to its CEACAM6-targeted technology and has structured collaborations to support manufacturing and regulatory activities.

Leadership at MabVax is anchored by Chief Executive Officer David Hansen, who brings extensive experience in biopharmaceutical development and strategic partnerships. Under his guidance, the company has progressed its immunotherapy and imaging programs into human trials and continues to explore opportunities for additional antibody constructs directed against tumor-associated antigens.

By integrating targeted therapy with diagnostic imaging, MabVax aims to establish a comprehensive approach to cancer care, from early detection through therapeutic intervention. As a clinical-stage entity, the company remains focused on trial enrollment, regulatory interactions and potential alliances that could accelerate the development and commercial availability of its novel oncology products.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.02
• 52-Week Range: $0.00 to $0.30
• Volume: 1,333 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MBVXQ Stock Analysis - Frequently Asked Questions

How have MBVXQ shares performed this year?

MabVax Therapeutics' stock was trading at $0.0230 at the start of the year. Since then, MBVXQ shares have increased by 0.0% and is now trading at $0.0230.

How do I buy shares of MabVax Therapeutics?

Shares of MBVXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:MBVXQ
• CIK: N/A
• Web: www.mabvax.com
• Phone: 858-259-9405
• Fax: 650-845-7800
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A